BofA analyst Jason Zemansky raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $581 from $456 and keeps a Neutral rating on the shares. The firm is increasing its near-term Rezdiffra forecasts after having conducted a small prescriber survey, but remains below long-term consensus, the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Cautious Outlook for Madrigal Pharmaceuticals Amid Competitive Pressures and Adoption Challenges
- Madrigal Pharmaceuticals price target raised to $670 from $560 at B. Riley
- CRNX, CYTK, MDGL, SLNO: Top Analyst Outlines Her ‘Top Biotech Ideas for 2026’
- Strong Adoption and Market Expansion Drive Buy Rating for Madrigal Pharmaceuticals’ Rezdiffra
- Madrigal price target raised to $620 from $568 at H.C. Wainwright